Cetuximab
Copyright policy )Cetuximab
Cetuximab (Erbitux; ImClone Systems/Bristol-Myers Squibb) is a monoclonal antibody that binds to the epidermal growth factor receptor, which is important in the growth of many cancers. In February 2004, it was granted accelerated approval by the US FDA for the treatment of metastatic colorectal cancer on the basis of tumour response rates in Phase II trials.
- University of North Carolina at Chapel Hill United States
- UNC Lineberger Comprehensive Cancer Center United States
ErbB Receptors, Clinical Trials as Topic, Treatment Outcome, Antibodies, Monoclonal, Cetuximab, Humans, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Colorectal Neoplasms, Signal Transduction
ErbB Receptors, Clinical Trials as Topic, Treatment Outcome, Antibodies, Monoclonal, Cetuximab, Humans, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Colorectal Neoplasms, Signal Transduction
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).78 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!